NCT04660097 2026-04-08
Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Completed
Clinical Trials
24 trialsNCT04877821 2026-04-02
NeoSACT
Guangdong Provincial People's Hospital
Phase 2 Completed
NCT05001971 2026-01-15
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy
Hunan Cancer Hospital
Phase 2 Completed
NCT04574284 2025-05-28
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT04996758 2024-12-12
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
Sun Yat-sen University
Phase 2 Completed
NCT04691388 2024-12-05
A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor
Zhejiang Cancer Hospital
Phase 2 Completed
NCT04860700 2024-06-12
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Peking Union Medical College Hospital
Phase 2 Completed
NCT05493995 2024-05-09
PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Completed
NCT04271813 2024-04-23
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
Shanghai Changzheng Hospital
Phase 2 Completed
NCT03906058 2023-10-25
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
Sun Yat-sen University
Phase 2 Completed
NCT04790409 2023-09-14
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
Zhejiang Cancer Hospital
Phase 2 Completed
NCT06015035 2023-08-29
Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Tang-Du Hospital
Phase 2 Completed
NCT04055792 2023-06-28
Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Henan Cancer Hospital
Phase 2 Completed
NCT03743129 2023-06-12
ALTER-L029
Peking University Cancer Hospital & Institute
Phase 2 Completed
NCT05130515 2023-01-31
CC-ANNIE
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT05206656 2022-11-23
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
Hunan Cancer Hospital
Phase 2 Completed
NCT03736837 2021-03-15
ALTER-L004
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT04002284 2020-07-29
Anlotinib in Metastatic HER2 Negative Breast Cancer
ChineseAMS
Phase 2 Completed
NCT04216082 2020-01-02
A Study of Anlotinib in Subjects With Advanced Malignancy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT02649361 2019-06-05
Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT01878448 2019-05-22
ALTN/STS
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT01874873 2019-05-21
ALTN/MTC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT03059797 2019-05-16
Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT01924195 2015-10-28
Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed